All data points from Fig 1. by Sara Hijazi (21656615)

“…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”

All data points from Fig 4. by Sara Hijazi (21656615)

“…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”

All data points from Fig 9. by Sara Hijazi (21656615)

“…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”

All data points from Fig 7. by Sara Hijazi (21656615)

“…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”

All data points from Fig 6. by Sara Hijazi (21656615)

“…Following a remyelination period of 5 weeks, PV interneuron properties were only partially recovered, suggesting that transient juvenile demyelination leads to long-lasting impairments of PV interneuron function. …”

Decreased striatal Drd1 mRNA expression during the early, but not late, phase of motor skill learning. by Yu Qian (153240)

Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation. by Arindam P. Ghosh (317870)

“…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”

(R)-albuterol decreases cytokine mRNA levels in activated T cells by Marcela A Ferrada (41716)

“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”

Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study by Jilles M. Fermont (3746068)

“…In total, 291 of 714 individuals experienced 762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospitalised AECOPD. …”

Cephalometric measurement points. by Lijuan Liu (136685)

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…</p><p>Conclusions</p><p>In a mostly HIV patient population, RPR titer can show more than four-fold spontaneous increase or decrease within 1–3 months. …”

Mice carrying 100P mutations show region-specific decreases in proportions of PV-expressing cells. by Malgorzata Borkowska (3166719)

“…<p>(<b>A</b>) Significant decreases in the proportions of PV+ cells were observed in fSSp, SSp, vAud and in Vis, but not MPFC. …”

Role of Ser77 in ACER3 catalytic site. by Jae Kyo Yi (13570063)

Linearity of ACER3 activity assay. by Jae Kyo Yi (13570063)

Structure of ADPR2 and ACER3. by Jae Kyo Yi (13570063)

The kinetics of ACER3 and mutants. by Jae Kyo Yi (13570063)

Inhibitor assay of ACER3. by Jae Kyo Yi (13570063)

HPLC chromatogram of standard NBD-C₁₂-FA. by Jae Kyo Yi (13570063)

Comparison between TLC and HPLC used in this study. by Jae Kyo Yi (13570063)

Suggested ACER3 catalytic mechanism. by Jae Kyo Yi (13570063)